Danaher (NYSE:DHR) Given New $250.00 Price Target at UBS Group

Danaher (NYSE:DHR) had its target price decreased by UBS Group from $270.00 to $250.00 in a report released on Wednesday morning,Benzinga reports. UBS Group currently has a buy rating on the conglomerate’s stock.

Other equities analysts have also recently issued reports about the stock. Evercore raised their price objective on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a research note on Tuesday. Wells Fargo & Company reduced their price objective on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Rothschild & Co Redburn set a $205.00 price objective on shares of Danaher in a research note on Friday, April 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research note on Friday, March 27th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research note on Thursday, January 29th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $243.20.

Danaher Price Performance

Shares of DHR stock opened at $184.11 on Wednesday. Danaher has a 52-week low of $180.03 and a 52-week high of $242.80. The stock has a market cap of $130.30 billion, a PE ratio of 35.61, a PEG ratio of 2.64 and a beta of 0.95. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87. The firm’s 50 day moving average price is $197.17 and its two-hundred day moving average price is $214.35.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm earned $1.88 earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, analysts forecast that Danaher will post 8.39 EPS for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.40 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s payout ratio is 30.95%.

Insider Buying and Selling at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Danaher

A number of hedge funds and other institutional investors have recently made changes to their positions in DHR. Sivia Capital Partners LLC boosted its position in shares of Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after purchasing an additional 119 shares in the last quarter. First Trust Advisors LP lifted its position in Danaher by 34.5% in the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after acquiring an additional 14,217 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Danaher by 40.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after acquiring an additional 886 shares in the last quarter. Ieq Capital LLC lifted its position in Danaher by 64.2% in the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after acquiring an additional 29,592 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its position in Danaher by 30.7% in the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after acquiring an additional 325 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and modestly higher FY outlook — Danaher reported $2.06 non‑GAAP EPS (above consensus) and raised FY2026 EPS guidance to $8.35–$8.55, which supports the stock’s fundamental earnings trajectory. Danaher Reports First Quarter 2026 Results
• Positive Sentiment: Bioprocessing and Life Sciences momentum — Management cited strong demand in bioprocessing and life‑sciences tools (double‑digit strength in some businesses), a key driver of beat‑and‑raise dynamics. Reuters: Danaher beats first-quarter profit estimates
• Positive Sentiment: Some analyst support remains — Evercore raised its target to $232 (outperform), indicating pockets of continued buy‑side confidence despite cuts elsewhere. Evercore raises Danaher target
• Neutral Sentiment: €2.98B senior notes offering — Danaher priced €3.0B of euro‑denominated senior notes across several maturities; proceeds boost liquidity (and may fund M&A like Masimo) but add long‑term debt. PR Newswire: Euro‑denominated senior notes offering
• Negative Sentiment: Revenue miss and Diagnostics softness — Revenue rose ~3.7% to $5.95B, below consensus; core revenue growth was modest and Diagnostics (Cepheid/respiratory) was a clear weak spot, which pressured sentiment despite the EPS beat. Yahoo Finance deep dive
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), amplifying near‑term selling pressure even though many retain buy/overweight stances. MarketScreener: JPMorgan target change
• Negative Sentiment: Acquisition/integration and insider selling concerns — Investors are parsing the planned Masimo acquisition and near‑term capital allocation; recent insider sales headlines add to the cautious tone. QuiverQuant analysis

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.